U.S. markets open in 7 hours 53 minutes

RAPT Therapeutics, Inc. (RAPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.73+0.58 (+3.20%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close18.15
Open18.60
Bid0.00 x 800
Ask0.00 x 800
Day's Range18.52 - 19.58
52 Week Range10.52 - 41.86
Volume87,632
Avg. Volume220,838
Market Cap459.921M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.45
Earnings DateNov 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Benzinga

      5 Value Stocks In The Healthcare Sector

      Understanding Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued. Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching: Global Cord Blood (NYSE:CO) - P/E: 6.8 RAPT Therapeutics (NASDAQ:RAPT) - P/E: 0.71 OpGen (NASDAQ:OPGN) - P/E: 0.68 Onconova Therapeutics (NASDAQ:ONTX) - P/E: 1.59 Greenlane Holdings (NASDAQ:GNLN) - P/E: 9.89 Global Cord Blood saw an increase in earnings per share from 0.15 in Q1 to 0.16 now. Global Cord Blood does not have a dividend yield, which investors should be aware of when considering holding onto such a stock. RAPT Therapeutics saw a decrease in earnings per share from -0.51 in Q2 to -0.6 now. RAPT Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock. OpGen's earnings per share for Q3 sits at -0.4, whereas in Q2, they were at -0.49. OpGen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock. Onconova Therapeutics has reported Q3 earnings per share at -0.03, which has increased by 25.0% compared to Q2, which was -0.04. Onconova Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock. Greenlane Holdings has reported Q3 earnings per share at -0.35, which has increased by 23.91% compared to Q2, which was -0.46. Greenlane Holdings does not have a dividend yield, which investors should be aware of when considering holding onto such a stock. These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector. See more from BenzingaClick here for options trades from BenzingaUnusual Options Activity Insight: QuantumScapeUnderstanding Exxon Mobil's Unusual Options Activity© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • RAPT Therapeutics (NASDAQ:RAPT) Is In A Strong Position To Grow Its Business
      Simply Wall St.

      RAPT Therapeutics (NASDAQ:RAPT) Is In A Strong Position To Grow Its Business

      Just because a business does not make any money, does not mean that the stock will go down. For example, although...

    • RAPT Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
      GlobeNewswire

      RAPT Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present at the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 12:00 pm Eastern Time. To access the live webcast and subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations. About RAPT Therapeutics, Inc.RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets, including hematopoietic progenitor kinase 1 (HPK1) and general control nonderepressible 2 (GCN2), that are in the discovery stage of development. Investor Contact:Sylvia Wheelerswheeler@wheelhouselsa.com Media Contact:Aljanae Reynoldsareynolds@wheelhouselsa.com